Yana Najjar
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Yana Najjar sits in the upper quartile of US sponsors by registered trial count (#1,604 of 15,742 sponsors by registered trial count).
Yana Najjar: 8 sponsored US clinical trials, 5 recruiting.
Yana Najjar sponsors 8 registered US clinical trials on ClinicalTrials.gov, 5 of them currently recruiting, and 2 completed. 0 of these trials are in Phase 3-4 (later-stage) and 6 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Melanoma, with 4 trials.
Upper-quartile sponsor footprint
Yana Najjar sits in the upper quartile of the sponsor corpus (#1,604 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Open and recent trials
8 total, page 1 of 1
Evaluation of Hypoxia in Primary Melanoma
NCT06831071
RP1 in Primary Melanoma to Reduce the Risk of Sentinel Lymph Node Metastasis
NCT06216938
Safety of SBRT With Anti-PD1 and Anti-IL-8 for the Treatment of Multiple Metastases in Advanced Solid Tumors and Melanoma
NCT04572451
Evolution of Metabolic and Immune Dysfunction in In-transit Melanoma
NCT04658303
A Trial of Pembrolizumab and Metformin Versus Pembrolizumab Alone in Advanced Melanoma
NCT03311308
Nivolumab Plus Axitinib in Patients With Anti-PD1 Refractory Advanced Melanoma
NCT04493203
Dose-seeking Study of Pembrolizumab Plus Vemurafenib and Cobimetinib Advanced Melanoma
NCT02818023
Neoadjuvant Combination Biotherapy With Pembrolizumab and High Dose IFN-alfa2b
NCT02339324
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 5 |
| Phase 2 | 1 |
What is open in the Yana Najjar pipeline
5 recruiting of 8 indexed (63% open); 2 completed (25%).
Phase mix: 0 late (III/IV) vs 6 early (I/II) (early-phase heavy).
Top condition: Melanoma (4 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Yana Najjar: open-pipeline peers nationwide
Peers matched on 8 registered trials and 63% open enrollment, not the therapeutic-area sidebar.
Yana Najjar sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 8 trials (± recruiting share)
- AB Science · 8 trials · 25% recruiting
- Abbott Point of Care · 8 trials · 25% recruiting
- Abeona Therapeutics · 8 trials · 0% recruiting
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) · 8 trials · 38% recruiting
Sponsors near 63% open enrollment (± trial volume)
- Canadian Cancer Trials Group · 63% recruiting · 16 trials
- CellSight Technologies · 63% recruiting · 8 trials
- Cook Children's Health Care System · 63% recruiting · 8 trials
- Nurix Therapeutics · 63% recruiting · 8 trials
Related
What to do with this Yana Najjar page
8 registered trials is a research-attention snapshot, not an endorsement of Yana Najjar or any single study.
- 5 of Yana Najjar's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Melanoma is the condition Yana Najjar studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Melanoma trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Yana Najjar pipeline card: 8 registered trials from official public datasets.Report a data error.